Two allogeneic hematopoietic stem cell transplantations without the use of blood-product support

Haematologica

Volumn 90, Issue 9, 2005, Pages 1292-1294

  Wandt, Hannes ^a,b   Schaefer Eckart, Kerstin ^a   Wilhelm, Martin ^a  

^a KLINIKUM NÜRNBERG   (Germany)

^b Medical Dep 5   (Germany)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Jehovah's Witness; Myeloablative conditioning; Treosulfan

Indexed keywords

CYTARABINE; DAUNORUBICIN; FLUDARABINE; TREOSULFAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD; BLOOD DONOR; CANCER REGRESSION; CASE REPORT; FEMALE; HUMAN; PATIENT ABANDONMENT; RELIGION;

ADULT; BUSULFAN; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; JEHOVAH'S WITNESSES; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS;

EID: 25444466209     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. 9/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998;91:3601-6.
2. Schaefer-Eckart K, Frank M, Wilhelm M, Wandt H. Routine prophylactic platelet transfusions are not necessary for patients in clinical stable condition after autologous peripheral stem cell transplantation: updated results in 106 patients. Blood 2004;104:3636[abstract].
3. Schmidmaier R, Oellerich M, Baumgart J, Emmerich B, Meinhardt G. Treosulfan induced apoptosis in AML cells is accompanied by translocation of PKCδ and enhanced by bryostatin-1. Exp Hematol 2004;32:76-86.
4. Fichtner I, Becker M, Baumgart J. Antileukemic activity of treosulfan in xenografted human acute lymphoblastic leukemias (ALL). Eur J Cancer 2003;39:801-7.
5. Casper J, Knauf W, Blau I, Ruutu T, Volin L, Wandt H, et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic blood stem cell transplantation. Blood 2004;103:725-31.
6. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russel N, de Elvira CR, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100:4310-6.
7. Ballen KK, Becker PS, Yeap BY, Mathews B, Henry DH, Ford PA. Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol 2004;22:4087-94.